SI2281037T1 - Faktor VII polipeptidi, ki so modificirani, in njihove uporabe - Google Patents

Faktor VII polipeptidi, ki so modificirani, in njihove uporabe

Info

Publication number
SI2281037T1
SI2281037T1 SI200931368T SI200931368T SI2281037T1 SI 2281037 T1 SI2281037 T1 SI 2281037T1 SI 200931368 T SI200931368 T SI 200931368T SI 200931368 T SI200931368 T SI 200931368T SI 2281037 T1 SI2281037 T1 SI 2281037T1
Authority
SI
Slovenia
Prior art keywords
modified
factor vii
vii polypeptides
polypeptides
factor
Prior art date
Application number
SI200931368T
Other languages
English (en)
Slovenian (sl)
Inventor
Edwin L. Madison
Christopher Thanos
Original Assignee
Catalyst Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences, Inc. filed Critical Catalyst Biosciences, Inc.
Publication of SI2281037T1 publication Critical patent/SI2281037T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200931368T 2008-04-11 2009-04-10 Faktor VII polipeptidi, ki so modificirani, in njihove uporabe SI2281037T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12402108P 2008-04-11 2008-04-11
EP09730852.2A EP2281037B1 (en) 2008-04-11 2009-04-10 Factor vii polypeptides that are modified and uses thereof
PCT/US2009/002248 WO2009126307A2 (en) 2008-04-11 2009-04-10 Factor vii polypeptides that are modified and uses thereof

Publications (1)

Publication Number Publication Date
SI2281037T1 true SI2281037T1 (sl) 2016-02-29

Family

ID=40872757

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931368T SI2281037T1 (sl) 2008-04-11 2009-04-10 Faktor VII polipeptidi, ki so modificirani, in njihove uporabe

Country Status (23)

Country Link
US (4) US8519103B2 (enExample)
EP (4) EP2687596B1 (enExample)
JP (3) JP2011517942A (enExample)
KR (1) KR101623602B1 (enExample)
CN (2) CN105039291A (enExample)
AU (1) AU2009234390B2 (enExample)
BR (1) BRPI0911060B1 (enExample)
CA (1) CA2721038C (enExample)
CO (1) CO6331368A2 (enExample)
DK (2) DK2281037T3 (enExample)
EA (2) EA020818B1 (enExample)
ES (3) ES2560236T3 (enExample)
HU (1) HUE026937T2 (enExample)
IL (2) IL208373A (enExample)
MX (2) MX344220B (enExample)
MY (1) MY161581A (enExample)
NZ (1) NZ588322A (enExample)
PL (1) PL2281037T3 (enExample)
PT (1) PT2281037E (enExample)
SG (2) SG190560A1 (enExample)
SI (1) SI2281037T1 (enExample)
TW (2) TWI465247B (enExample)
WO (1) WO2009126307A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005110453A2 (en) 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
EP2428218A1 (en) * 2005-10-21 2012-03-14 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
NZ574140A (en) 2006-07-05 2012-02-24 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
SI2147096T1 (sl) * 2007-04-13 2015-07-31 Catalyst Biosciences, Inc., Modificirani polipeptidi faktorja VII in njihove uporabe
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CN102596231B (zh) 2009-06-25 2016-01-20 北卡罗来纳-查佩尔山大学 嵌合因子ⅶ分子
EP2591099B1 (en) 2010-07-09 2020-11-18 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US20140046277A1 (en) * 2011-04-15 2014-02-13 Gamma Therapeutics, Inc. Fast-clotting wound dressings
WO2012149463A1 (en) * 2011-04-29 2012-11-01 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules with enhanced half life and methods of use
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
CA2870621C (en) * 2012-02-14 2022-08-09 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
BR112014025737A2 (pt) 2012-04-16 2017-07-04 Cantab Biopharmaceuticals Patents Ltd método para administrar um agente terapêutico, método para prevenir a entrada de um agente terapêutico, método para modular a velocidade de liberação de um agente terapêutico, agente terapêutico, formas de dosagem, método de tratamento de uma doença e kit de partes
BR112015001628A2 (pt) 2012-07-25 2017-11-07 Catalyst Biosciences Inc polipeptídeos de fator x modificados e uso dos mesmos
US20150259665A1 (en) 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
CN104704118A (zh) 2012-10-15 2015-06-10 诺和诺德保健Ag（股份有限公司） 凝血因子vii多肽
PL3165232T3 (pl) 2012-12-24 2019-12-31 Coagulant Therapeutics Corporation Krótko działające polipeptydy czynnika VII
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
WO2015055692A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
AR099328A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados de factor vii
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
LT3149163T (lt) * 2014-05-26 2020-09-25 Academisch Ziekenhuis Leiden Prohemostatiniai baltymai, skirti kraujavimo gydymui
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
MX2017008541A (es) 2015-01-02 2017-12-04 Dyax Corp Anticuerpos biespecificos contra calicreina y factor xii del plasma.
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
BR112018001202A2 (en) 2015-07-21 2018-09-25 Dyax Corp. monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US20190153119A1 (en) * 2016-04-14 2019-05-23 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with neovascularization
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
WO2018005716A2 (en) * 2016-07-01 2018-01-04 Denali Therapeutics Inc. Albumin variants for enhanced serum half-life
US20210284715A1 (en) * 2017-02-06 2021-09-16 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
KR20200050961A (ko) * 2017-09-05 2020-05-12 글래디에이터 바이오사이언시스 인코포레이티드 줄기세포로의 페이로드의 전달
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
WO2019071028A1 (en) 2017-10-04 2019-04-11 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
US20210095283A1 (en) * 2018-01-04 2021-04-01 Avidity Biosciences, Inc. Heteroduplex nucleic acid molecules and uses thereof
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2020010189A1 (en) * 2018-07-06 2020-01-09 Children's Medical Center Corporation Methods and compositions for analyzing platelets by mass cytometry
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CN114375297A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 Una亚酰胺及其用途
WO2020247782A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
EP4086344A4 (en) * 2019-12-30 2024-01-10 Nanjing GenScript Biotech Co., Ltd. METHOD FOR CONSTRUCTING A LIBRARY OF GENE MUTATIONS
JP7759719B2 (ja) * 2020-02-27 2025-10-24 オムロン株式会社 流量測定装置
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
US12385818B2 (en) 2023-02-14 2025-08-12 Saudi Arabian Oil Company Modeling gas desorption in a subsurface reservoir
CN118126161B (zh) * 2024-03-26 2025-10-24 福州大学 一种凝血因子FXIa的多肽抑制剂及其在抗凝治疗方面的应用
CN119372186B (zh) * 2024-12-30 2025-04-15 深圳市卫光生物制品股份有限公司 一种重组人凝血因子vii的纯化方法和应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
AU651573B2 (en) 1990-01-29 1994-07-28 Novo Nordisk Health Care Ag Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2001522230A (ja) 1997-02-14 2001-11-13 アメリカン・レツド・クロス トランスジェニック動物乳房組織における活性ヒト第▲ｉｘ▼因子の発現
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE19937219A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6806063B2 (en) 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
AU2001256148A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Subcutaneous administration of coagulation factor vii
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
CN1304049C (zh) 2000-05-10 2007-03-14 诺沃挪第克健康护理股份公司 包含因子VIIα和因子XIII的药物组合物
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
MXPA03001984A (es) * 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
HUP0301246A3 (en) 2000-09-13 2005-12-28 Novo Nordisk Healthcare Ag Human coagulation factor vii variants
HUP0301267A3 (en) 2000-10-02 2005-12-28 Novo Nordisk Healthcare Ag Factor vii glycoforms
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
JP2004517950A (ja) 2001-02-05 2004-06-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチド及び第ｖｉｉｉ因子ポリペプチドの組合された使用
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
CA2447023A1 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2003004681A2 (en) 2001-07-03 2003-01-16 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
ATE532858T1 (de) 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag Menschliche gerinnungsfaktor-vii-polypeptide
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
HUP0402158A2 (hu) 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
WO2003031585A2 (en) 2001-10-09 2003-04-17 Dendreon Corporation Transmembrane serine protease 25
JP3862996B2 (ja) 2001-10-31 2006-12-27 帝人ファイバー株式会社 ポリトリメチレンテレフタレートフィラメント糸およびその製造方法
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030134794A1 (en) 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
EP1458407A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
EP1361284A1 (en) 2002-05-10 2003-11-12 Direvo Biotech AG Process for generating sequence-specific proteases by directed evolution and use thereof
WO2003104394A2 (en) 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
CA2489596A1 (en) 2002-06-14 2003-12-24 Dyax Corporation Protein analysis
ES2363205T3 (es) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
WO2004005471A2 (en) 2002-07-02 2004-01-15 Dendreon Corporation Serine protease 16
EP1546202B1 (en) 2002-09-25 2007-08-22 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP4472526B2 (ja) 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US20060024289A1 (en) 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
MXPA05003493A (es) 2002-10-02 2005-09-30 Catalyst Biosciences Metodos para generar y seleccionar proteasas con especificidad alterada.
MXPA05009770A (es) 2003-03-18 2005-11-17 Novo Nordisk Healthcare Ag Metodo para la produccion de serina proteasas que contienen residuos de gla.
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
WO2004108763A2 (en) 2003-06-05 2004-12-16 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
WO2004110469A2 (en) 2003-06-13 2004-12-23 Novo Nordisk Health Care Ag Formulations comprising factor viia and a factor vii related polypeptide
US20060116324A1 (en) 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
EP1633866A1 (en) 2003-06-18 2006-03-15 Direvo Biotech AG New biological entities and the pharmaceutical or diagnostic use thereof
US7335504B2 (en) 2003-06-18 2008-02-26 Direvo Biotechnology Ag Engineered enzymes and uses thereof
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
WO2005023308A1 (en) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
EP1664291B1 (en) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
JP2007509843A (ja) 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子
WO2005051289A2 (en) 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins
WO2005068620A1 (en) 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
EP1713906A2 (en) 2004-02-03 2006-10-25 Novo Nordisk Health Care AG Coagulation factor vii/viia variants lacking functional lipid membrane binding domain
WO2005100556A2 (en) 2004-04-12 2005-10-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
WO2005110453A2 (en) 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
WO2005123119A2 (en) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
AU2005253749A1 (en) 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH)
JP2008503541A (ja) 2004-06-21 2008-02-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト グリコシル化分裂型因子ｖｉｉ変異体
WO2006014253A2 (en) 2004-07-02 2006-02-09 Genentech, Inc. Factor viia variants
WO2006008267A2 (en) 2004-07-16 2006-01-26 Novo Nordisk Health Care Ag Methods for optimizing forming viiia-based hemostatic treatment
EP1778838A2 (en) 2004-08-02 2007-05-02 Novo Nordisk Health Care AG Conjugation of fvii
PL1781782T3 (pl) 2004-08-17 2010-10-29 Csl Behring Gmbh Zmodyfikowane polipeptydy zależne od witaminy K
WO2006035057A1 (en) 2004-09-29 2006-04-06 Novo Nordisk Health Care Ag Modified proteins
WO2006067198A2 (en) 2004-12-22 2006-06-29 Direvo Biotech Ag Targeted use of engineered enzymes
WO2006067230A1 (en) 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
AU2006239117A1 (en) 2005-04-28 2006-11-02 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
ES2434032T3 (es) 2005-06-17 2013-12-13 Novo Nordisk Health Care Ag Compuestos de FVIIA diméricos y multiméricos
JP2009515508A (ja) * 2005-08-19 2009-04-16 ネオス テクノロジーズ インコーポレイテッド グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ
EP1919498A2 (en) 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
US20080268521A1 (en) 2005-09-01 2008-10-30 Novo Nordisk Healthcare A/G Purification of Coagulation Factor VII Polypeptides
WO2007031559A2 (en) * 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
JP2009508510A (ja) 2005-09-21 2009-03-05 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US20090221484A1 (en) 2005-10-07 2009-09-03 Novo Nordisk A/S Use of Factor VII Polypeptides for Neuroprotection
EP2428218A1 (en) 2005-10-21 2012-03-14 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
NZ574140A (en) 2006-07-05 2012-02-24 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
JP5122562B2 (ja) 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
WO2008078189A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
SI2147096T1 (sl) 2007-04-13 2015-07-31 Catalyst Biosciences, Inc., Modificirani polipeptidi faktorja VII in njihove uporabe
US9102962B2 (en) 2007-10-16 2015-08-11 Shiu Nan Chen Production method for solid cultured active mushroom mycelium and fruit-body metabolites (AMFM) products thereof
GB0800938D0 (en) * 2008-01-18 2008-02-27 Ge Healthcare Uk Ltd Multiplex cell signalling assay
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
US8266208B2 (en) 2008-11-06 2012-09-11 Joseph Mahon Method and system for sharing documents among members of an online community
CN102596231B (zh) 2009-06-25 2016-01-20 北卡罗来纳-查佩尔山大学 嵌合因子ⅶ分子
CN201753815U (zh) 2010-07-27 2011-03-02 江森自控空调冷冻设备(无锡)有限公司 三通结构
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
BR112015001628A2 (pt) 2012-07-25 2017-11-07 Catalyst Biosciences Inc polipeptídeos de fator x modificados e uso dos mesmos
CN104704118A (zh) 2012-10-15 2015-06-10 诺和诺德保健Ag（股份有限公司） 凝血因子vii多肽
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Also Published As

Publication number Publication date
EP2281037A2 (en) 2011-02-09
US9476037B2 (en) 2016-10-25
US20140044701A1 (en) 2014-02-13
EP2687596A2 (en) 2014-01-22
US8519103B2 (en) 2013-08-27
HK1194096A1 (en) 2014-10-10
JP5659312B1 (ja) 2015-01-28
TW200942258A (en) 2009-10-16
HK1192905A1 (en) 2014-09-05
NZ588322A (en) 2012-03-30
TWI465247B (zh) 2014-12-21
TWI538916B (zh) 2016-06-21
SG193779A1 (en) 2013-10-30
BRPI0911060A2 (pt) 2015-10-13
IL225740A0 (en) 2013-06-27
CN102083971B (zh) 2015-08-05
IL208373A0 (en) 2010-12-30
AU2009234390B2 (en) 2013-10-31
AU2009234390A1 (en) 2009-10-15
MY161581A (en) 2017-04-28
US20090291890A1 (en) 2009-11-26
EP2679678B1 (en) 2016-05-18
DK2281037T3 (en) 2016-01-11
EA201001628A1 (ru) 2011-06-30
ES2556596T3 (es) 2016-01-19
JP5976021B2 (ja) 2016-08-23
HUE026937T2 (en) 2016-07-28
CA2721038A1 (en) 2009-10-15
KR20110008084A (ko) 2011-01-25
MX344220B (es) 2016-12-07
US10160961B2 (en) 2018-12-25
ES2577055T3 (es) 2016-07-12
EP2687596B1 (en) 2016-01-06
EA020818B1 (ru) 2015-02-27
PT2281037E (pt) 2016-01-27
SG190560A1 (en) 2013-06-28
US20160376577A1 (en) 2016-12-29
US20190055534A1 (en) 2019-02-21
MX2010011170A (es) 2010-11-01
US11203749B2 (en) 2021-12-21
EA201301350A1 (ru) 2014-07-30
PL2281037T3 (pl) 2016-05-31
CO6331368A2 (es) 2011-10-20
TW201431877A (zh) 2014-08-16
JP2014113157A (ja) 2014-06-26
CN105039291A (zh) 2015-11-11
BRPI0911060B1 (pt) 2022-04-05
HK1154273A1 (zh) 2012-04-13
IL225740A (en) 2015-04-30
EP3064580A1 (en) 2016-09-07
WO2009126307A3 (en) 2009-12-10
WO2009126307A2 (en) 2009-10-15
ES2560236T3 (es) 2016-02-18
EA024760B1 (ru) 2016-10-31
EP2687596A3 (en) 2014-04-23
CA2721038C (en) 2018-07-31
JP2011517942A (ja) 2011-06-23
JP2015017093A (ja) 2015-01-29
DK2687596T3 (da) 2016-02-29
EP2679678A1 (en) 2014-01-01
EP2281037B1 (en) 2015-11-11
CN102083971A (zh) 2011-06-01
KR101623602B1 (ko) 2016-06-07
IL208373A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
IL225740A0 (en) Adapted factor vii polypeptides and uses thereof
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
IL208718A0 (en) Modified factor ix polypeptides and uses thereof
IL237314A (en) Insulin polypeptides are modified and their uses
GB0916576D0 (en) Polypeptides and uses thereof
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
IL210804A (en) Benzylidenehydrazides and their uses
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL207096A0 (en) Modified leptin polypeptides and their uses
IL217551A0 (en) Bifunctional stapled polypeptides and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
GB0702020D0 (en) Peptides and their use
GB0708376D0 (en) Novel polypeptides and uses thereof
SI2483292T1 (sl) Variantni polipeptidi lovd in njihove uporabe
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en) Leukolectins and uses thereof
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
GB0702021D0 (en) Peptides and their use
GB0905790D0 (en) Novel polypeptides and use thereof
GB0812277D0 (en) Antibody and uses thereof
GB0800698D0 (en) F2 polypeptides and usesthereof
GB0800701D0 (en) F10 Polypeptides and uses thereof
GB0800700D0 (en) F9 polypeptides and uses thereof